The amount of time available to pathologists with which to perform research is becoming limited due to an increasing manpower shortage in pathology, decreased reimbursement, and increased workload. This is occurring at the same time as demands escalate for pathologists to develop new companion tests, correlate the molecular findings with traditional methods, and assist in the development of individualized medicine. This study examined whether cytotechnologists may be integrated into a research team that uses their expertise in understanding pathology and clinical disease to provide interpretations of experiments that traditionally were performed by pathologists. METHODS: Cytotechnologists worked with pathologists to choose blocks for tissue microarrays (TMAs) and to interpret immunohistochemically stained TMA slides. The pathologist met with the cytotechnologist to review the study design. The cytotechnologists reviewed the slides and blocks and chose the most appropriate blocks for the TMA. Either 10% or all of the slides/blocks selected for TMA construction were reviewed by the supervising pathologist. The final selections were given to the TMA technologist to make the TMA. A minimum of 10% of the immunohistochemically stained TMA slides were reviewed by the supervising pathologist. RESULTS: A total of 32 TMAs were created with 6 cytotechnologists collaborating with 6 pathologists. Immunohistochemical stains of 190 TMAs were interpreted by 4 cytotechnologists collaborating with 3 pathologists. All the TMAs and TMA interpretation data were used successfully for the research for which they were designed.
INTRODUCTION
Many pathologists have the impression that their workload has been increasing recently. Many of the major pathology organizations in the United States and in other countries have studied the issue. [1] [2] [3] [4] The College of American Pathologists Workforce Project Work Group has reported what to our knowledge is one of the most detailed studies to date, 1,2 which found that pathologists on average work 49.2 hours per week, which is similar to the time reported 25 years earlier. However, such studies provide data regarding the total amount of time devoted to work as well as the distribution of time for various types of activities, but these data are not available for historical times for comparison. Many academic pathologists now devote a much greater percentage of their time to clinical service, with less time available for research. The problem is compounded by an increasing demand for pathologist time to assist clinicians with biomarker studies to support their clinical studies.
Cytotechnologists are a resource that is available in most institutions and represent a pool of morphologists that may be available to participate in research activities. Historically, the field was initiated by the work of Papanicolaou and Traut, who provided evidence of the value of uterine cervical cytology in the early detection of cervical carcinoma. 5 The value of the cytological assessment of specimens collected from nearly all body sites has expanded the role of cytotechnologists to the majority of organ systems. To be able to evaluate the range of specimens that cytotechnologists examine, their training includes the study of the normal and pathological anatomy of a wide range of sites. At the same time that the cytotechnologists have been developing a larger role in the evaluation of many organ systems, their role in cervical cytology is becoming less important due to the increasing use of computerized image analysis, the recommendations by the American Congress of Obstetricians and Gynecologists for less frequent screening, and human papillomavirus testing as alternatives to the routine review of Papanicolaou tests by cytotechnologists. The availability of cytotechnologists with training in microscopic anatomy and pathology has, in recent years, provided a trained workforce in some institutions for the performance of digital image analysis; quantitative immunohistochemistry; fluorescence in situ hybridization; circulating tumor cell testing; tissue slide review and marking for molecular oncology testing; and special stain evaluation, including for acid-fast Bacillus in some institutions. 6 Tissue microarrays (TMAs) are recipient paraffin blocks that contain multiple cores of tissue harvested from paraffin-embedded donor tissue blocks with the histology/ pathology of interest. A single section of a TMA has tissue from hundreds of examples of the tumor or tissue of interest. TMAs provide a powerful tool for biomarker discovery and validation. 7 However, TMAs can be very timeconsuming to make. The typical workflow for the production of a TMA starts with the selection of a pool of patients for whom there are paraffin-embedded tissue blocks available that contain the disease of interest. The slides are collected and reviewed to confirm the diagnosis and to select the blocks with sufficient tumor. Current federal regulations require the preservation of diagnostic material in the blocks for a minimum of 10 years. The reviewer must confirm that the production of the TMA will not compromise the preservation of the diagnostic material. Once the slides are reviewed, the blocks also have to be reviewed to determine the thickness of tissue remaining in the blocks. For example, if there is only 0.3 mm of tissue left in the block, few sections will be able to cut from the block before the core is exhausted. If 2.0 mm to 2.5 mm of tissue remain in the block, many more sections can be made from the TMA. Tissues selected on hematoxylin and eosin section review occasionally are suboptimal at the time of block review. It is important that many slides and blocks be reviewed to optimize the TMA construction. The process is iterative and frequently requires the review of thousands of slides as well as hundreds to thousands of blocks to make a single TMA. Therefore, although a high-quality TMA is time-consuming to make, they facilitate multiple research projects. Cytotechnologists collaborating with pathologists have the skills to create high-quality TMAs.
MATERIALS AND METHODS
The construction of all of the TMAs was approved by the Mayo Clinic institutional review board.
TMA Construction
At the beginning of a project to construct a TMA, a cytotechnologist was assigned to the project. The cytotechnologist reviewed the study design with the supervising pathologist. The review included the design of the TMA such as the size and number of cores from each donor block, the production of a single recipient block or the production of additional blocks (so-called sister blocks), and the type of pathology or histology to be included. In addition, glass slides representing target tissues were reviewed. When the pathologist and cytotechnologist were confident that the cytotechnologist would be able to identify the target tissues, the cytotechnologist was given the slides from potential donor tissues to review. If the cytotechnologist had any questions regarding the slides during the review, the supervising pathologist was available to review the slides with the cytotechnologist. The cytotechnologist selected multiple examples of the most appropriate tissues based on the hematoxylin and eosin review and requested the corresponding blocks from the clinical archive. The cytotechnologist reviewed the slides and blocks together to choose the best block or blocks to be used in the construction of the TMA. The cytotechnologist marked the blocks with permanent marker to indicate the area from which the donor cores should be taken. When the selection of donor blocks was complete, the supervising pathologist reviewed the selection before construction of the TMA.
Two approaches to review were performed. The pathologist either 1) reviewed all of the selections or 2) reviewed approximately 10% of the selections as well as any cases in which the cytotechnologist had a question concerning their selection. After the final approval of the selections, the blocks were given to the histotechnologists with expertise in TMA construction.
TMA Stain Interpretation
At the beginning of a project to interpret TMA stains, a cytotechnologist was assigned to the project. The cytotechnologist reviewed the study design with the supervising pathologist. The scoring criteria were determined by the pathologist. The criteria may include the tissue to be assessed (invasive tumor, noninvasive tumor, benign tissue, stroma, etc), stain location (nuclear, cytoplasmic, or membrane), quantity of staining, intensity of staining, H-score, Allred scoring, or other parameters. The cytotechnologist and pathologist reviewed stained glass slides or digital images of the stained slides and agreement on the scoring of sample cases was established. After the review, the cytotechnologist scored the TMA cores using the agreed upon criteria. The pathologist had the option of reviewing all of the cores but the majority reviewed only a minimum of 10%. A minimum of 5% of the cores were selected randomly by either an individual in the laboratory other than the cytotechnologist who performed the analysis for review or by a random number generator (random.org) and the cytotechnologist selected a minimum of 5% of additional cores, focusing on challenging cases. If the pathologist did not agree with the scoring of the cytotechnologist, the pathologist decided how to proceed, which may have included a review of all of the cores or discontinuing the involvement of the cytotechnologist.
RESULTS

TMA Construction
A total of 32 TMAs were constructed with the assistance of 6 cytotechnologists with the supervision of 6 pathologists. The target tissues included breast, gastrointestinal, liver, and skin tumors. The TMAs included biopsies from 4036 patients. Pathologists and researchers reviewed the donor block and coring region selections. The overall rate of disagreement between the pathologist and the cytotechnologist regarding the optimal selection of block and core was 4.29%. As the group gained experience with the process, there was steady improvement, with a disagreement rate of 1.10% noted for the latest TMA. The majority of the disagreements involved decisions regarding which was the best area to core, not whether the area contained an area of interest. The other main reason for disagreement involved the thickness of the block. Incident light on a paraffin block is highly scattered in all directions, which gives the block its white appearance but makes determination of the thickness of the tissue in the block difficult because the deep margin of the tissue cannot always be easily visualized. In our experience, the cytotechnologists can judge the depth of tissue remaining in the block better than the pathologists. The cytotechnologists tried to choose blocks with a minimum of 2 mm of tissue in the block; however, when there are areas of interest that may not be represented in many blocks that are believed to be thinner, it is a judgement call regarding whether to include the block in the TMA.
TMA Core Scoring
Immunohistochemical stains for a total of 190 TMAs were reviewed by a total of 4 cytotechnologists with 3 supervising pathologists. The overall disagreement rate between the pathologists and the cytotechnologists regarding scoring of the TMAs was 3.43%. This finding is in the range that would be expected for 2 readers of most immunohistochemical stains. Previous studies have shown interobserver variability of up to 20% in the interpretation of immunohistochemical stains, 8 which can be improved with training, 9 as we have done in this study. The differences in the interpretation of the immunostains did not involve any specific antibodies or cell compartments such as membrane, cytoplasmic, or nuclear. The majority of the disagreements were related to intensity (such as 1 1 vs 21) rather than presence (such as the number of CD3-positive cells infiltrating a tumor). All the TMAs and TMA interpretation data have been used successfully for the research for which they were designed.
DISCUSSION
The mission of the Pathology Research Core (PRC) of the Mayo Clinic is to facilitate high-quality, tissue-based research at the institution. One of the problems that the PRC identified was long delays in the construction and analysis of TMAs due to the lack of availability of pathologists to participate in the studies. To meet the needs of the research community, the PRC recruited cytotechnologists with an interest in research to pilot a different approach.
Original Article
The PRC recognized that it is critical to have committed pathologists involved in all aspects of the projects, but it may not be necessary for them to perform all of the functions. The PRC requires all projects to have a designated pathologist. The pathologist reviews the study design and sample glass slides with the cytotechnologist who is going to perform the core selection or core analysis. They agree on the criteria for selection or scoring and resolve any issues. In the initial phase of the pilot program, the pathologist reviewed 10% of the cases for quality control of the process. A minimum of 5% random selection was performed by someone other than the cytotechnologist involved in the project or by a random number generator (random.org) to eliminate any chance of bias as well as another 5% of the cases to include any cases in which the cytotechnologist had any questions regarding the morphology. We encountered no problems in either the construction of TMAs or the interpretation of the TMA slides. At the time of integration of cytotechnologists into the PRC, some projects that had been on hold for years were able to be completed. This approach allows the anatomic pathologists and the cytotechnologists to collaborate to deliver quality research endeavors in a timely fashion as anatomic pathology research availability is shrinking.
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